BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Rating of “Moderate Buy” from Analysts

BioNTech SE Sponsored ADR (NASDAQ:BNTX) has been assigned a consensus rating of “Moderate Buy” from the eighteen analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, twelve have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $131.60.

A number of equities analysts have recently issued reports on the stock. Truist Financial upgraded shares of BioNTech to a “strong-buy” rating in a research report on Wednesday, March 25th. Leerink Partners lowered shares of BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 price objective on the stock. in a research report on Monday, February 2nd. The Goldman Sachs Group reiterated a “buy” rating on shares of BioNTech in a research report on Wednesday, March 11th. Wells Fargo & Company lowered their price objective on shares of BioNTech from $150.00 to $140.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of BioNTech in a research report on Tuesday, March 17th.

BioNTech Stock Performance

Shares of BNTX opened at $94.13 on Wednesday. The company has a current ratio of 8.80, a quick ratio of 8.74 and a debt-to-equity ratio of 0.01. The firm has a market cap of $23.80 billion, a PE ratio of -16.01 and a beta of 1.36. The company’s 50 day simple moving average is $96.58 and its 200-day simple moving average is $100.91. BioNTech has a 12-month low of $79.52 and a 12-month high of $124.00.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Saturday, February 14th. The company reported ($0.39) earnings per share (EPS) for the quarter. The business had revenue of $1.06 billion for the quarter. BioNTech had a negative return on equity of 5.30% and a negative net margin of 44.39%. As a group, equities analysts predict that BioNTech will post -4.71 EPS for the current year.

BioNTech announced that its board has approved a share repurchase plan on Thursday, May 7th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the company to buy up to 4.2% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling

In other BioNTech news, COO Sierk Poetting sold 50,000 shares of the firm’s stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $110.56, for a total value of $5,528,000.00. Following the completion of the sale, the chief operating officer owned 399,387 shares of the company’s stock, valued at approximately $44,156,226.72. This trade represents a 11.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 19.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in BNTX. Larson Financial Group LLC raised its stake in shares of BioNTech by 86.4% during the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after buying an additional 127 shares during the last quarter. EFG International AG acquired a new position in shares of BioNTech during the 4th quarter worth $29,000. Caitong International Asset Management Co. Ltd raised its stake in shares of BioNTech by 520.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock worth $30,000 after buying an additional 260 shares during the last quarter. Huntington National Bank raised its stake in shares of BioNTech by 1,266.7% during the 3rd quarter. Huntington National Bank now owns 410 shares of the company’s stock worth $40,000 after buying an additional 380 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of BioNTech by 118.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after buying an additional 305 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.